There is a renaissance in the use of hydroxychloroquine (HCQ). Since the 1950s it has been widely used in autoimmune conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), including use in pregnancy due to its efficacy and presumed safety. There is also excitement that it may have a far wider application, and clinical trials of HCQ are taking place in cancer, diabetes mellitus 1 and cardiovascular disease.
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A case-control analysis from the SLE in a multiethnic group cohort (the Lupus in Minorities: Nature versus Nurture (LUMINA) cohort) showed a better survival of patients with SLE who were taking HCQ. 2 Some rheumatologists now advocate the use of HCQ in all patients with SLE 3,4 due to its immunomodulatory and antithrombotic effect. 3, 5, 6 The use of HCQ in the United Kingdom has steadily increased over the past 10 years; the number of dispensed 200 mg tablets rose from approximately 1.5 million in 2006 to 3.5 million in 2016. 7 This upwards trend is likely to continue as increasing scientific evidence on the beneficial effect of HCQ in other conditions becomes available. HCQ's role in antiphospholipid syndrome (APS) for example is particularly exciting. 8 Emerging evidence suggests HCQ's beneficial effects in thrombotic and obstetric APS. [9] [10] [11] Further, the European Medical Agency has recently granted an orphan license for the use of HCQ in APS (EU/3/16/1820).
In the management of SLE and RA HCQ has a favourable systemic safety profile when compared to other disease-modifying antirheumatic drugs (DMARDs) such as azathioprine, methotrexate or mycophenolate mofetil. HCQ-induced disturbances of renal and hepatic function, skeletal muscle and cardiotoxicity are considered rare 12 and DMARD blood monitoring is usually not recommended. 13 Moreover, HCQ's favourable safety profile allows for its use in pregnancy and lactation, [14] [15] [16] and Østensen et al. published their guideline for the use on anti-rheumatics in pregnancy more than a decade ago. 16 Their systematic review of several hundred pregnancies exposed to HCQ did not find any adverse pregnancy outcomes and recommended HCQ as the antimalarial of choice in women planning for a pregnancy because HCQ is compatible with pregnancy and breastfeeding. Similarly, the British Society of Rheumatology guidelines on HCQ in pregnancy concluded that HCQ is safe and is recommended as the 'immunemodulator of choice in pregnant women', 17 which was reinforced by the European League against Rheumatism in March 2017. 18 The main concern is the development of a retinopathy due to HCQ's affinity and toxicity to melanin-containing cells, resulting in irreversible damage. It is yet to be fully established how HCQ induces retinal toxicity. Animal studies suggest that the earliest detectable changes of HCQ toxicity are found in the ganglion cells and photoreceptors (referred to as the neural retina) and that changes in the retinal pigment epithelium (RPE) occur later. 19 In vitro studies on cultured RPE cells suggest that HCQ alters RPE lysosome pH, resulting in higher levels of lipofuscin, a pigment that accumulates with age and is associated with photoreceptor degeneration. 20, 21 In early stages the retinopathy is asymptomatic and slowly progressive, but in its advanced stage, HCQ retinopathy produces a profound irreversible loss of central vision which is associated with clinically visible changes in the macula (Bull's eye maculopathy). Table 1 outlines patients' symptoms and clinical findings in the different stages.
It is possible to detect HCQ retinopathy prior to any visual symptoms using a combination of functional and anatomical assessments. Formal testing of the central 10 degrees of visual field can detect paracentral sensitivity reduction, 22 and early anatomical changes can be identified using the new imaging modalities of spectral-domain optical coherence tomography (SD-OCT) and fundus autofluorescence imaging (FAF). 23 Moreover, multifocal electroretinogram has been suggested as an effective screening test. 24 In a recent publication, a cohort of 2361 American patients taking HCQ underwent visual field testing and SD-OCT. The overall prevalence of HCQ retinopathy was estimated to be 7.5% after five years of use, rising to 20% after 20 years. The highest risk factors for retinopathy were duration of HCQ therapy, daily dose (>5 mg/kg actual body weight, odds ratio (OR) 5.67 (4.14-7.79)), renal impairment (OR 2.08 (1.44-3.01)) and concurrent tamoxifen therapy (OR 4.59 (2.05-10.27)), also known to cause a retinopathy). 25 Table 2 illustrates the prevalence of retinal toxicity of HCQ in relation to dose and duration.
HCQ prescribers thus know which patients are at high risk but cannot identify any patients with early disease. Stopping treatment at the earliest stages of retinopathy can prevent development of severe vision loss. The high prevalence of retinal problems and availability of modern retinal imaging has led to the update of the screening recommendations published by the American Academy of Ophthalmology in 2016 23 and by the Royal College of Ophthalmologists.
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Regular screening with field test, SD-OCT and FAF of patients taking HCQ is recommended, with patients attending the hospital eye service for an initial screen within six months of starting treatment, and annually after five years of therapy. Any patient starting treatment who is in a higher risk group (e.g. taking >5 mg/kg day, or taking tamoxifen concurrently) should have annual screening from the outset.
Unfortunately, HCQ-related retinal changes and irreversibility of HCQ are more prevalent than previously thought so we encourage all prescribers of HCQ and chloroquine to liaise with their local ophthalmologists to help set up a screening service.
In conclusion, advances in ophthalmic imaging techniques provide methods to diagnose HCQinduced retinal changes before patients become symptomatic. Screening recommendations for patients treated with HCQ by the American Academy of Ophthalmology and the Royal College of Ophthalmologists provide a systematic framework to capture patients with early HCQrelated retinal changes and stop treatment prior to the development of irreversible retinal damage. Given a rise in the trend of prescription of HCQ, it is crucial to implement these guidelines into the daily practice of physicians who prescribe HCQ so that it is used safely. 
